John Libbey Eurotext

European Journal of Dermatology

No recurrence of nivolumab-induced idiopathic thrombocytopenic purpura in a metastatic melanoma patient switched to ipilimumab Ahead of print

Figures

  • Figure 1
Authors
Department of Dermatology,
Kyoto University Graduate School of Medicine,
Kyoto, Japan

Immune checkpoint inhibitors, including antibodies against programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4), have markedly improved the overall survival of patients with metastatic melanoma, but their use is associated with unique immune-related adverse effects (irAEs) [1, 2]. Consensus guidelines regarding the treatment of the commonest irAEs, including rash, colitis, hepatitis, endocrinopathies, and pneumonitis, have been established, but rare adverse effects such as idiopathic [...]